All Oncology News

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Efrat Dotan, MD, discusses patient factors to consider during treatment planning for metastatic pancreatic cancer.

Komal Jhaveri, MD, FACP, discusses management strategies for ocular toxicities and other ADC-related adverse effects in breast cancer.

Mayo Clinic discovery of breast cancer treatment resistance can lead to new hope for some patients.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

OncLive® and the Ruesch Center at Georgetown Lombardi announce the 2025 Luminary Award winners in gastrointestinal cancers.

Rebecca Dent, MD, MSc, discusses data from the TROPION-Breast02 trial evaluating first-line Dato-Dxd in immunotherapy-ineligible triple-negative breast cancer

Harry P. Erba, MD, PhD; and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.

The FDA set a March 29, 2026, PDUFA date for LNTH-2501, a PET imaging agent targeting SSTR-positive neuroendocrine tumors.

The FDA granted orphan drug designation to DPTX3186 in gastric cancer.

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

The FDA granted orphan drug designation to an exosome-based therapy for glioblastoma multiforme.

Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.

Vepugratinib-based treatment was safe and active in FGFR3-altered metastatic urothelial cancer.

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes.

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.

Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

PlasmaSure received FDA breakthrough device designation for low- to intermediate-risk non–muscle-invasive bladder cancer.

Carma L. Bylund, PhD, discussed the findings from a pilot study of a fellowship-level program for clinical trial communication skills.

Yale Cancer Center researchers publish promising study of dual inhibition of PD1 and macrophage migration inhibitory factor.

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

Two belzutifan-based combinations met their respective primary efficacy end points of DFS and PFS in the phase 3 LITESPARK-022 and LITESPARK-011 trials.

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.